Theravance Biopharma Inc
TBPH18.730USD
+0.160+0.86%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
949.09MMarket Cap
32.30P/E TTM
More Details of Theravance Biopharma Inc Company
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Theravance Biopharma Inc Info
Ticker SymbolTBPH
Company nameTheravance Biopharma Inc
IPO dateMay 16, 2014
CEOWinningham (Rick E)
Number of employees97
Security typeOrdinary Share
Fiscal year-endMay 16
AddressUgland House, South Church Street
CityGEORGE TOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCayman Islands
Postal codeKY1-1104
Phone16508086000
Websitehttps://www.theravance.com/
Ticker SymbolTBPH
IPO dateMay 16, 2014
CEOWinningham (Rick E)
Company Executives of Theravance Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.23M
-5.16%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
201.01K
-3.36%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
131.38K
-12.65%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
114.14K
-14.03%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
58.06K
+22.46%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
+33.82%
Mr. Jeremy T. Grant
Mr. Jeremy T. Grant
Independent Director
Independent Director
28.54K
+59.52%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.23M
-5.16%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
201.01K
-3.36%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
131.38K
-12.65%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
114.14K
-14.03%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
U.S.
64.38M
0.00%
Europe
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
18.77%
Weiss Asset Management
14.72%
Newtyn Management, LLC
9.77%
BlackRock Institutional Trust Company, N.A.
6.38%
Irenic Capital Management LP
5.45%
Other
44.92%
Shareholders
Shareholders
Proportion
Madison Avenue Partners LP
18.77%
Weiss Asset Management
14.72%
Newtyn Management, LLC
9.77%
BlackRock Institutional Trust Company, N.A.
6.38%
Irenic Capital Management LP
5.45%
Other
44.92%
Shareholder Types
Shareholders
Proportion
Hedge Fund
57.74%
Investment Advisor/Hedge Fund
18.49%
Investment Advisor
17.29%
Individual Investor
4.25%
Research Firm
3.35%
Pension Fund
0.30%
Bank and Trust
0.10%
Venture Capital
0.03%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
292
47.17M
93.66%
-4.29M
2025Q2
288
48.49M
96.98%
-9.87M
2025Q1
306
49.02M
97.92%
-10.33M
2024Q4
307
49.22M
100.10%
-11.44M
2024Q3
311
50.46M
103.15%
-9.84M
2024Q2
312
51.86M
106.61%
-21.43M
2024Q1
304
56.26M
115.67%
-11.52M
2023Q4
301
56.96M
111.33%
-13.16M
2023Q3
314
59.36M
109.50%
-14.46M
2023Q2
331
61.03M
103.70%
-24.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madison Avenue Partners LP
9.51M
18.89%
--
--
Jun 30, 2025
Weiss Asset Management
7.46M
14.81%
--
--
Jun 30, 2025
Newtyn Management, LLC
4.95M
9.83%
+192.60K
+4.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.29M
6.54%
+259.25K
+8.54%
Jun 30, 2025
Irenic Capital Management LP
2.76M
5.48%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.16M
4.28%
+76.97K
+3.70%
Jun 30, 2025
Park West Asset Management LLC
1.80M
3.57%
-5.16K
-0.29%
Jun 30, 2025
Winningham (Rick E)
1.29M
2.57%
-15.39K
-1.18%
Aug 20, 2025
D. E. Shaw & Co., L.P.
1.00M
1.99%
+81.46K
+8.85%
Jun 30, 2025
Oasis Management Company Ltd.
1.12M
2.22%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.21%
Inspire Fidelis Multi Factor ETF
1.04%
Janus Henderson Small Cap Growth Alpha ETF
0.79%
Invesco NASDAQ Future Gen 200 ETF
0.57%
Global X Aging Population ETF
0.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.42%
State Street SPDR S&P Pharmaceuticals ETF
0.35%
ALPS Medical Breakthroughs ETF
0.31%
iShares U.S. Pharmaceuticals ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.2%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.21%
Inspire Fidelis Multi Factor ETF
Proportion1.04%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.79%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.57%
Global X Aging Population ETF
Proportion0.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.42%
State Street SPDR S&P Pharmaceuticals ETF
Proportion0.35%
ALPS Medical Breakthroughs ETF
Proportion0.31%
iShares U.S. Pharmaceuticals ETF
Proportion0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0.2%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Theravance Biopharma Inc?
The top five shareholders of Theravance Biopharma Inc are:
Madison Avenue Partners LP holds 9.51M shares, accounting for 18.89% of the total shares.
Weiss Asset Management holds 7.46M shares, accounting for 14.81% of the total shares.
Newtyn Management, LLC holds 4.95M shares, accounting for 9.83% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.29M shares, accounting for 6.54% of the total shares.
Irenic Capital Management LP holds 2.76M shares, accounting for 5.48% of the total shares.
Madison Avenue Partners LP holds 9.51M shares, accounting for 18.89% of the total shares.
Weiss Asset Management holds 7.46M shares, accounting for 14.81% of the total shares.
Newtyn Management, LLC holds 4.95M shares, accounting for 9.83% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.29M shares, accounting for 6.54% of the total shares.
Irenic Capital Management LP holds 2.76M shares, accounting for 5.48% of the total shares.
What are the top three shareholder types of Theravance Biopharma Inc?
The top three shareholder types of Theravance Biopharma Inc are:
Madison Avenue Partners LP
Weiss Asset Management
Newtyn Management, LLC
Madison Avenue Partners LP
Weiss Asset Management
Newtyn Management, LLC
How many institutions hold shares of Theravance Biopharma Inc (TBPH)?
As of 2025Q3, 292 institutions hold shares of Theravance Biopharma Inc, with a combined market value of approximately 47.17M, accounting for 93.66% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.32%.
What is the biggest source of revenue for Theravance Biopharma Inc?
In FY2024, the -- business generated the highest revenue for Theravance Biopharma Inc, amounting to -- and accounting for --% of total revenue.
